These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7137396)

  • 21. Further evidence of a dose-response threshold for haloperidol in psychosis.
    Stone CK; Garve DL; Griffith J; Hirschowitz J; Bennett J
    Am J Psychiatry; 1995 Aug; 152(8):1210-2. PubMed ID: 7625474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma haloperidol levels: clinical response and fancy mathematics.
    Van Putten T; Marder SR; Mintz J
    Arch Gen Psychiatry; 1985 Aug; 42(8):835-8. PubMed ID: 4015328
    [No Abstract]   [Full Text] [Related]  

  • 23. Beyond the therapeutic window: a case presentation.
    Schulz SC; Butterfield L; Garicano M; Narasimhachari N; Friedel RO
    J Clin Psychiatry; 1984 May; 45(5):223-5. PubMed ID: 6725212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
    Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coadministration of fluvoxamine increases serum concentrations of haloperidol.
    Daniel DG; Randolph C; Jaskiw G; Handel S; Williams T; Abi-Dargham A; Shoaf S; Egan M; Elkashef A; Liboff S
    J Clin Psychopharmacol; 1994 Oct; 14(5):340-3. PubMed ID: 7806690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients.
    Ko GN; Korpi ER; Kirch DG
    J Clin Psychopharmacol; 1989 Jun; 9(3):186-90. PubMed ID: 2661607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations.
    Gerlach J; Behnke K; Heltberg J; Munk-Anderson E; Nielsen H
    Br J Psychiatry; 1985 Sep; 147():283-8. PubMed ID: 3904885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Somatosensory-evoked potential changes during haloperidol treatment of chronic schizophrenics.
    Saletu B; Saletu M; Itil T; Marasa J
    Biol Psychiatry; 1971; 3(4):299-307. PubMed ID: 5163816
    [No Abstract]   [Full Text] [Related]  

  • 29. Negative correlation between alpha-1-acid-glycoprotein plasma level and response to haloperidol in the acute treatment of schizophrenia.
    Levinson I; Levine S
    Biol Psychiatry; 1995 Aug; 38(3):198-200. PubMed ID: 7578667
    [No Abstract]   [Full Text] [Related]  

  • 30. Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder.
    Volavka J; Cooper TB; Czobor P; Meisner M
    Psychopharmacol Bull; 1996; 32(1):75-9. PubMed ID: 8927679
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Risperidone in the treatment of schizophrenia.
    Marder SR; Meibach RC
    Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma haloperidol and reduced haloperidol concentrations in a geriatric population.
    Chang WH; Jann MW; Chiang TS; Lin HN; Hu WH; Chien CP
    Neuropsychobiology; 1996; 33(1):12-6. PubMed ID: 8821369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia.
    Balant-Gorgia AE; Eisele R; Balant L; Garrone G
    Eur Arch Psychiatry Neurol Sci; 1984; 234(1):1-4. PubMed ID: 6489392
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum prolactin as a correlate of clinical response to haloperidol.
    Van Putten T; Marder SR; Mintz J
    J Clin Psychopharmacol; 1991 Dec; 11(6):357-61. PubMed ID: 1770154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Haloperidol and reduced haloperidol plasma levels in selected schizophrenic patients.
    Ereshefsky L; Davis CM; Harrington CA; Jann MW; Browning JL; Saklad SR; Burch NR
    J Clin Psychopharmacol; 1984 Jun; 4(3):138-42. PubMed ID: 6736273
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive changes in acute schizophrenia with brief neuroleptic treatment.
    Wahba M; Donlon PT; Meadow A
    Am J Psychiatry; 1981 Oct; 138(10):1307-10. PubMed ID: 7294185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Use of haloperidol in high doses in schizophrenia. Clinical, biochemical and pharmacokinetic study].
    Scatton B; Zarifian E; Bianchetti G; Cuche H; Loo H; Morselli PL
    Encephale; 1982; 8(1):1-8. PubMed ID: 7094868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
    Kane JM; Davis JM; Schooler N; Marder S; Casey D; Brauzer B; Mintz J; Conley R
    Am J Psychiatry; 2002 Apr; 159(4):554-60. PubMed ID: 11925292
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risperidone in treatment-refractory schizophrenia.
    Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
    Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.